Sona Nanotech Inc. (SNANF)
USD 0.18
(0.0%)
USD 0.18
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 418.29 Thousand CAD | -7.67% |
| 2022 | 453.04 Thousand CAD | 196.48% |
| 2021 | 152.81 Thousand CAD | -88.99% |
| 2020 | 1.38 Million CAD | 138.15% |
| 2019 | 582.82 Thousand CAD | 181.87% |
| 2018 | -711.86 Thousand CAD | -3808.76% |
| 2017 | -18.21 Thousand CAD | -103.18% |
| 2016 | 573.18 Thousand CAD | -71.79% |
| 2015 | 2.03 Million CAD | 36.94% |
| 2014 | 1.48 Million CAD | 131.28% |
| 2013 | 641.51 Thousand CAD | 284.66% |
| 2012 | -347.4 Thousand CAD | 68.89% |
| 2011 | -1.11 Million CAD | -293.59% |
| 2010 | -283.68 Thousand CAD | 75.46% |
| 2009 | -1.15 Million CAD | -13.3% |
| 2008 | -1.02 Million CAD | 83.34% |
| 2007 | -6.12 Million CAD | -4607.05% |
| 2006 | -130.11 Thousand CAD | -49374.9% |
| 2005 | -263.00 CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | 567.8 Thousand CAD | 5.24% |
| 2024 Q1 | 400.91 Thousand CAD | -4.16% |
| 2024 Q2 | 539.52 Thousand CAD | 34.57% |
| 2023 FY | 418.29 Thousand CAD | -7.67% |
| 2023 Q2 | -47.68 Thousand CAD | -108.93% |
| 2023 Q4 | 418.29 Thousand CAD | -3.1% |
| 2023 Q1 | 533.87 Thousand CAD | 17.84% |
| 2023 Q3 | 431.69 Thousand CAD | 1005.35% |
| 2022 Q2 | -74.81 Thousand CAD | 86.45% |
| 2022 Q3 | 193.4 Thousand CAD | 358.52% |
| 2022 Q4 | 453.04 Thousand CAD | 134.25% |
| 2022 FY | 453.04 Thousand CAD | 196.48% |
| 2022 Q1 | -551.99 Thousand CAD | -461.22% |
| 2021 Q1 | 258.54 Thousand CAD | -81.37% |
| 2021 Q3 | -279.62 Thousand CAD | 41.13% |
| 2021 FY | 152.81 Thousand CAD | -88.99% |
| 2021 Q4 | 152.81 Thousand CAD | 154.65% |
| 2021 Q2 | -474.95 Thousand CAD | -283.7% |
| 2020 Q3 | 978.34 Thousand CAD | 6.79% |
| 2020 Q1 | 433.15 Thousand CAD | -25.68% |
| 2020 FY | 1.38 Million CAD | 138.15% |
| 2020 Q4 | 1.38 Million CAD | 41.87% |
| 2020 Q2 | 916.1 Thousand CAD | 111.5% |
| 2019 Q2 | 388.14 Thousand CAD | 189.23% |
| 2019 FY | 582.82 Thousand CAD | 181.87% |
| 2019 Q1 | -435 Thousand CAD | 38.89% |
| 2019 Q4 | 582.82 Thousand CAD | 0.56% |
| 2019 Q3 | 579.54 Thousand CAD | 49.31% |
| 2018 Q3 | -224.07 Thousand CAD | -25.43% |
| 2018 Q1 | 120.47 Thousand CAD | 761.53% |
| 2018 FY | -711.86 Thousand CAD | -3808.76% |
| 2018 Q4 | -711.86 Thousand CAD | -217.69% |
| 2018 Q2 | -178.64 Thousand CAD | -248.28% |
| 2017 Q3 | -150.54 Thousand CAD | -158.68% |
| 2017 Q2 | 256.56 Thousand CAD | -7.06% |
| 2017 Q1 | 276.04 Thousand CAD | -51.84% |
| 2017 FY | -18.21 Thousand CAD | -103.18% |
| 2017 Q4 | -18.21 Thousand CAD | 87.9% |
| 2016 Q4 | 573.18 Thousand CAD | -2.66% |
| 2016 FY | 573.18 Thousand CAD | -71.79% |
| 2016 Q3 | 588.86 Thousand CAD | -7.64% |
| 2016 Q2 | 637.57 Thousand CAD | -70.66% |
| 2016 Q1 | 2.17 Million CAD | 6.94% |
| 2015 Q3 | 2.26 Million CAD | 18.43% |
| 2015 Q4 | 2.03 Million CAD | -10.4% |
| 2015 Q2 | 1.91 Million CAD | 15.61% |
| 2015 Q1 | 1.65 Million CAD | 11.63% |
| 2015 FY | 2.03 Million CAD | 36.94% |
| 2014 FY | 1.48 Million CAD | 131.28% |
| 2014 Q2 | 915.33 Thousand CAD | 19.58% |
| 2014 Q3 | 1.13 Million CAD | 23.5% |
| 2014 Q4 | 1.48 Million CAD | 31.26% |
| 2014 Q1 | 765.45 Thousand CAD | 19.32% |
| 2013 Q4 | 641.51 Thousand CAD | 602.08% |
| 2013 Q1 | -41.59 Thousand CAD | 88.03% |
| 2013 Q2 | -303.13 Thousand CAD | -628.77% |
| 2013 Q3 | -127.77 Thousand CAD | 57.85% |
| 2013 FY | 641.51 Thousand CAD | 284.66% |
| 2012 FY | -347.4 Thousand CAD | 68.89% |
| 2012 Q1 | -174.78 Thousand CAD | 84.35% |
| 2012 Q2 | -17.45 Thousand CAD | 90.01% |
| 2012 Q3 | -640.86 Thousand CAD | -3571.32% |
| 2012 Q4 | -347.4 Thousand CAD | 45.79% |
| 2011 FY | -1.11 Million CAD | -293.59% |
| 2011 Q2 | -457.16 Thousand CAD | -959.91% |
| 2011 Q1 | -43.13 Thousand CAD | 84.8% |
| 2011 Q4 | -1.11 Million CAD | -3297.85% |
| 2011 Q3 | -32.86 Thousand CAD | 92.81% |
| 2010 FY | -283.68 Thousand CAD | 75.46% |
| 2010 Q4 | -283.68 Thousand CAD | 48.06% |
| 2010 Q1 | -899.39 Thousand CAD | 22.21% |
| 2010 Q3 | -546.14 Thousand CAD | 22.65% |
| 2010 Q2 | -706.03 Thousand CAD | 21.5% |
| 2009 Q3 | -1.56 Million CAD | -103.5% |
| 2009 FY | -1.15 Million CAD | -13.3% |
| 2009 Q4 | -1.15 Million CAD | 25.89% |
| 2009 Q1 | -445.7 Thousand CAD | 56.33% |
| 2009 Q2 | -766.59 Thousand CAD | -71.99% |
| 2008 FY | -1.02 Million CAD | 83.34% |
| 2008 Q4 | -1.02 Million CAD | 71.26% |
| 2008 Q1 | -10.32 Million CAD | -68.54% |
| 2008 Q3 | -3.55 Million CAD | 45.12% |
| 2008 Q2 | -6.46 Million CAD | 37.33% |
| 2007 Q4 | -6.12 Million CAD | 27.98% |
| 2007 FY | -6.12 Million CAD | -4607.05% |
| 2007 Q2 | -10.13 Million CAD | -418.34% |
| 2007 Q1 | -1.95 Million CAD | -1403.19% |
| 2007 Q3 | -8.5 Million CAD | 16.12% |
| 2006 Q4 | -130.11 Thousand CAD | 86.58% |
| 2006 Q3 | -969.59 Thousand CAD | -987.94% |
| 2006 FY | -130.11 Thousand CAD | -49374.9% |
| 2006 Q1 | -220.00 CAD | 0.0% |
| 2006 Q2 | -89.12 Thousand CAD | -40410.0% |
| 2005 FY | -263.00 CAD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| American Bio Medica Corporation | 2.2 Million USD | 81.038% |
| Arrayit Corporation | 1.05 Million USD | 60.373% |
| Atlantic International Corp. | 236.49 Thousand USD | -76.874% |
| Biocept, Inc. | -788 Thousand USD | 153.084% |
| Bioqual, Inc. | -12 Million USD | 103.484% |
| CardioGenics Holdings Inc | 22.73 Thousand USD | -1739.566% |
| DermTech, Inc. | 17.65 Million USD | 97.63% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | -572.49 Million USD | 100.073% |
| HTG Molecular Diagnostics, Inc. | -7.37 Million USD | 105.67% |
| iMD Companies, Inc. | 1.11 Million USD | 62.515% |
| IDenta Corp. | 524.85 Thousand USD | 20.302% |
| Interpace Biosciences, Inc. | 7.69 Million USD | 94.563% |
| Integrative Health Technologies, Inc. | -26.95 Thousand USD | 1652.015% |
| InVitro International | -313.14 Thousand USD | 233.581% |
| Lumos Diagnostics Holdings Limited | 1.56 Million USD | 73.287% |
| Many Bright Ideas Technologies Inc. | -713.00 USD | 58767.461% |
| Medical Imaging Corp. | 3.79 Million USD | 88.966% |
| NovelStem International Corp. | 3.52 Million USD | 88.122% |
| Optigenex Inc. | 8.93 Million USD | 95.318% |
| PharmChem, Inc. | -1.49 Million USD | 127.991% |
| Proteome Sciences plc | 14.57 Million USD | 97.13% |
| Response Genetics, Inc | -13.08 Million USD | 103.197% |
| Rennova Health, Inc. | 14.82 Million USD | 97.179% |
| RushNet, Inc. | 4.8 Million USD | 91.287% |
| ScreenPro Security Inc. | 135.58 Thousand USD | -208.505% |
| Stella Diagnostics Inc. | 6.19 Million USD | 93.246% |
| StageZero Life Sciences Ltd. | 1.78 Million USD | 76.558% |
| Todos Medical Ltd. | 38.31 Million USD | 98.908% |